India, Nov. 13 -- Zealand Pharma A/S (ZLDPF.PK,ZEAL.CO), a biotechnology company focused on metabolic health, announced Friday that the European Commission has granted marketing authorization for Zeydovio (glepaglutide) to treat adults with short bowel syndrome (SBS).
The approval marks the first major advancement in SBS treatment in Europe in more than a decade and makes Zeydovio the first and only ready-to-use GLP-2 therapy to receive regulatory approval.
Zeydovio is a long-acting GLP-2 analog designed to improve intestinal function and reduce or eliminate patients' need for parenteral support. It is administered twice weekly through a ready-to-use, single-dose autoinjector. The authorization is valid across all European Union member st...